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Abstract
We investigated the influence of pathology data to improve patient outcomes in the treatment of high-grade cervical neoplasia in a
joint pathology and gynecology collaboration. Two of us (B.S.D. and M.D.) reviewed all cytology, colposcopy and surgical
pathology results, patient history, and pregnancy outcomes from all patients with loop electrosurgical excision procedure
specimens for a 33-month period (January 2011-September 2013). We used this to determine compliance to 2006 consensus
guidelines for the performance of loop electrosurgical excision procedure and shared this information in 2 interprofessional and
interdisciplinary educational interventions with Obstetrics/Gynecology and Pathology faculty at the end of September 2013. We
simultaneously emphasized the new 2013 guidelines. During the postintervention period, we continued to provide follow-up using
the parameters previously collected. Our postintervention data include 90 cases from a 27-month period (October 2013December 2015).
Our preintervention data include 331 cases in 33 months (average 10.0 per month) with 76% adherence to guidelines.
Postintervention, there were 90 cases in 27 months (average 3.4 per month) and 96% adherence to the 2013 (more conservative)
guidelines (P < .0001, w2 test). Preintervention, the rate of high-grade squamous intraepithelial lesion in loop electrosurgical
excision procedures was 44%, whereas postintervention, there was a 60% high-grade squamous intraepithelial lesion rate on loop
electrosurgical excision procedure (P < .0087 by 2-tailed Fisher exact test). The duration between diagnosis of low-grade
squamous intraepithelial lesion and loop electrosurgical excision procedure also increased significantly from a median 25.5
months preintervention to 54 months postintervention (P < .0073; Wilcoxon Kruskal-Wallis test). Postintervention, there was a
marked decrease of loop electrosurgical excision procedure cases as well as better patient outcomes. We infer improved patient
safety, and higher value can be achieved by providing performance-based pathologic data.
Keywords
American Society for Colposcopy and Cervical Pathology, cervical neoplasia, guidelines, high-grade squamous intraepithelial
lesion, indications, intervention, loop electrosurgical excision procedure
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Introduction

Table 1. Indications for LEEP Coded as Nonguideline Adherent.

Loop electrosurgical excision procedure (LEEP) for the
removal of the transformation zone in preinvasive cervical
disease has many advantages over a cold knife cone biopsy,
including performance in an office setting (rather than ambulatory surgery), less blood loss, better postprocedure viewing
of the squamocolumnar junction, and smaller but evaluable
specimens for pathology. 1 For these reasons, LEEP has
become the dominant means of initial intervention in cervical
cancer prevention.2-4 However, there is a corresponding concern that this intervention for prevention of cervical cancer is
over utilized, subjecting some patients to unjustified costs
and risks.1 Although LEEP has a favorable complication profile compared to other secondary interventions for cervical
cancer prevention, it does not eliminate the costs and potential risks of conization.1,5,6 Potentially unjustified LEEP
intervention is particularly troubling for patients of reproductive age as LEEP has been associated with adverse pregnancy
outcomes, most notably preterm delivery, although this is not
universally accepted.7-17
Guidelines direct the application of LEEP.18,19 In 2013
during discussion about the new American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines, one of us
noted a high number of LEEPs without high-grade squamous
intraepithelial lesion (HSIL; cervical intraepithelial lesion
[CIN] grade 2 or 3) compared to published expectations.
We therefore discussed a joint quality assurance and patient
safety project among the Departments of Pathology and
Obstetrics and Gynecology and the School of Public Health.
Our explanatory hypothesis was that clinicians were not
strictly following guideline indications, which led to unjustified procedures with lower yields and potentially unjustified
risk. We hypothesized that by reviewing cases in a collaborative fashion for indications and outcomes and then using these
data in an educational manner with continued follow-up, we
could improve high-value treatment of cervical intraepithelial
neoplasia. Therefore, we analyzed our indications and outcomes for almost 3 years prior to our intervention (January
1, 2011), conducted educational interventions in September
2013, and continued ongoing review for 27 subsequent
months (October 2013-December 2015).

Nonguideline adherent reasons for LEEP

Materials and Methods
Under our institutional review board # 1306049573, we
reviewed 421 sequential LEEPs performed at our institution
over a 5-year period (January 01, 2011-December 31, 2015)
in our Anatomic Pathology Laboratory Information System.a
The cases from January 2011 through September 2013 were
classified as preintervention. The cases from October 2013
through December 2015 were classified as postintervention.
We reviewed each LEEP result and determined the presence
or absence of HSIL. We also reviewed the indication for each
LEEP using pathology/cytology results and chart review and
then compared the indications to the current published

Colposcopy
Unsatisfactory colposcopy only (without a HSIL biopsy or Pap test)
Extension of a lesion into the endocervical canal with negative
ECC or cytobrush
Discrepancy with positive colposcopy and negative biopsy
Endocervical curettings with LSIL only
Cytology
ASC-H without biopsy findings
AGC NOS without findings on ECCs
Atypical endometrial cells only
Duration of LSIL less than 2 years
Patient findings
Patient preference (patients without other specific guideline
indications who requested a LEEP)
Patient risk factors for progression for dysplasia
Diabetes
Smoking
Multiple sexual partners
Remote history of cervical dysplasia
Rheumatoid arthritis
Remote history of breast cancer
Morbid obesity with polycystic ovarian syndrome
History of Lyme disease
Noncompliant patients or detainees in prison or not using
condoms
Abbreviations: AGC NOS, atypical glandular cells not otherwise specified;
ASC-H, atypical squamous cells cannot exclude HSIL; ECC, endocervical
curettings; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excision procedure; LSIL, low-grade squamous intraepithelial lesion.

guideline. During the chart review for the preintervention
group, we also reviewed for pregnancy outcomes. We used the
2006 ASCCP guidelines for our preintervention period and the
2013 guidelines for our postintervention period. The main outcome measure was the presence or absence of HSIL including
CIN 2 or 3. The goal of these comparisons was to provide data
that could motivate clinician behavioral change, if needed.
Summarized, the 2006 consensus guideline indications for
LEEP included the following—CIN 2-3 with adequate colposcopy; inadequate colposcopy; recurrent CIN 2-3; endocervical
curettings (ECC) with CIN 2-3; and 2 (or more) years of lowgrade squamous intraepithelial lesion (LSIL) persistence.18
Since the pathologic diagnosis of CIN 1-2 was unclear, our
review coded it per the gynecologists’ interpretation of CIN
2 because the gynecology interpretation initiates the procedure.
Another possible indication that we accepted as guideline
adherent was HSIL on Pap test with negative subsequent
biopsy (cytology and biopsies would ideally be reviewed prior
to intervention in this circumstance). Colposcopy was considered guideline adherent if the colposcopy and ECC were both
unsatisfactory. The reasons given by clinicians considered as
nonguideline adherent are summarized in Table 1.
The 2013 consensus guidelines are more complicated and
more conservative. 19 They feature immediate LEEP for
patients aged 25 years and older with HSIL on biopsy,
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Table 2. Indications and Outcomes for LEEPs From the Preintervention Period January 1, 2011 to September 30, 2013.*
Indication for LEEP

>CIN 2 on LEEP (%)

<CIN 2 on LEEP (%)

Total

138 (64)
4 (24)
4 (25)
0
0
0
0
0
0
0
0
146 (44)

79 (36)
13 (76)
12 (75)
6
8
8
14
17
2
2
24
185 (56)

217
17
16
6
8
8
14
17
2
2
24
331

Biopsy with HSIL
HSIL Pap
Persistent LSIL > 24 months
LSIL < 24 months
Indefinite biopsy (CIN 1-2 or cannot rule out HSIL)
ECC with LSIL
Colposcopy
ASC-H Pap (15) or AGC NOS Pap (2)
Atypical endometrial cells on Pap
Patient preference
Risk factors
Total

Abbreviations: AGC NOS, atypical glandular cells not otherwise specified; ASC-H, atypical squamous cells cannot exclude HSIL; CIN, cervical intraepithelial lesion;
ECC, endocervical curettings; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excision procedure; LSIL, low-grade squamous
intraepithelial lesion.
*These were the data used for the educational intervention.

persistent HSIL or atypical squamous cells, cannot rule out
HSIL (ASC-H) Pap tests of 12-month duration, and duration
of LSIL of 24 months. For women aged 21 to 24 years, the
guidelines are even more restrictive with immediate LEEP
recommended for these younger women with CIN 3 and observation preferred for CIN 2. Using the 2013 consensus guidelines, we also determined whether the LEEP was guideline
adherent for the postintervention group.
Statistical comparisons were made using 2-tailed Fisher
exact test (as there were many cross tabulations with small cell
counts) or w2 test. Statistical analyses were performed using
JMP version 11.0.b
The intervention started with a meeting by the pathologists
(B.D., M.F., and M.D.) and public health specialist (A.D.) with
the gynecologists (M.H. and P.C.), who were considered clinical experts in the treatment of cervical neoplasia. We presented our findings and asked for their advice. These leaders
critiqued our analysis and reviewed the charts on patients with
LEEPs the pathologists considered nonguideline adherent. For
example, Pathology had considered LEEPs for CIN 1-2 as
nonguideline adherent; however, the gynecologists explained
that they interpreted such equivocal cases as ‘‘HSIL.’’ Based on
the information they provided, we conducted further analysis.
After consensus agreement on the data analysis and its interpretation, the group set up 2 meetings.
First, we met with the entire faculty of Pathology on September 25, 2013 and then with Obstetrics/Gynecology
(OB/GYN) on September 26, 2013. Both groups received the
same presentations—first, the 2013 guidelines were reviewed,
and the results of the study to that date (Table 2) were presented, and then the 2006 guidelines and data on LEEPs were
reviewed. We deliberately left ample time for questions—for
Pathology 45 minutes and >1 hour for OB/GYN. In the Pathology meeting, only the faculty members were present; in contrast, both faculty and residents participated in the OB/GYN
intervention. Since the Pathology issue was equivocal diagnoses, the Pathology faculty agreed for a second review for

any biopsy with a diagnosis that might be interpreted as a
high-grade dysplasia (such as CIN 1-2).
As we anticipated, OB/GYN clinicians expressed concerns
about compromised patient safety attendant to more strictly
following guidelines and framed this concern in terms of
‘‘missing a case of cervical cancer or high-grade dysplasia,’’
particularly in the context of their practice in a tertiary care
referral center with high-acuity and complex cases. This
patient-oriented concern was addressed with specific performance data as noted in Table 2. We acknowledged that in any
particular patient, there might be good reasons to recommend a
LEEP that was not entirely guideline adherent; however, we
were also able to illustrate that the outcome results supported
national standards that it is safe to wait. The data also showed
that the chances of missing HSIL in the group of patients were
small. The percentage of LEEPs without HSIL was of concern
to the gynecologists, and they agreed that they should adopt
more stringent guidelines.
Our data and concerns were endorsed by our gynecology
authors. We also discussed that we would be reviewing individual dashboard data on a quarterly basis using a spreadsheet (Figure 1). The dashboard is generated by pathology. A
pathologist reviews relevant data and decides, based solely
upon pathology data, whether they consider the LEEP to be
guideline adherent. The list is sent to the gynecology clinical
leadership who reviews additional clinical and colposcopy
findings and follows up when necessary with individual clinicians. The follow-up is ongoing; however, a more broadbased tissue committee was instituted early in 2016, and
possible cases that are nonguideline adherent are now
referred to the formal tissue committee and reviewed in coordination with Gynecology.

Results
There were 421 total patients with 331 LEEP procedures from
the 33-month preintervention period and 90 LEEP procedures
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Figure 1. Example of quarterly dashboard sent to the Department of Obstetrics/Gynecology (OB/GYN; all identifiers were removed).

Figure 2. Histogram with box plot of patient age for all patients in our
study. The median age at loop electrosurgical excision procedure
(LEEP) was 31.1 years with 75% of patients <38 years.

subsequently. The age range of our patients was 19 to 67 years
(overall mean: 33.3 years, median: 31 years) and is shown in a
histogram (Figure 2) with superimposed box plot. Mean age of
our patients in the preintervention group was 33.1 years (median: 33, range: 19-65), whereas the postintervention group was
slightly, but not significantly, older with a mean of 34.4 years
(median: 31, range: 22-67). Of importance to the clinical audience, 75% of our patients were aged 38 years, highly relevant
for adverse pregnancy outcomes. Among our initial group of 81
preintervention patients who did not have guideline adherent
indications for LEEP, 2 patients were categorized as ‘‘LEEP of
cervix complicating pregnancy,’’ and a third patient had preterm labor, albeit with multiple risk factor comorbidities.

Table 2 compares preintervention indications for LEEP with
the presence of detected HSIL. The strongest indication for
LEEP was a previous biopsy with HSIL; the majority (64%)
of such cases demonstrated CIN 2 or above on the LEEP specimen. In contrast, when HSIL was noted on the Pap test only
(ie, biopsy was discordant and did not have HSIL) or the indication was persistent LSIL, a much smaller percentage of cases
showed HSIL on the LEEP specimen. In addition, no case of
HSIL was found following less conservative indications.
Table 3 summarizes the results of our intervention. The
number of LEEPs fell dramatically from an average of 10 per
month in the preintervention period to an average of 3.4 per
month in the postintervention period. The percentage of cases
adherent to guidelines rose from an overall rate of 76% to 96%
of cases, respectively. These results were highly statistically
significant. When we further analyzed the cases per year, it
appears that the number of LEEPs was already falling; however, there was no improvement trend for the percentage of
cases that were guideline adherent during the preintervention
period. We cannot explain why the number of LEEPs fell prior
to the intervention. Over time, the dramatic initial decrease in
the number of LEEPs has reversed slightly, possibly because it
takes time to accumulate cases that are guideline adherent by
persistence of LSIL findings. Importantly, the improved percentage of guideline adherent cases has remained relatively
stable. Our purpose was to decrease the number of nonguideline adherent LEEPs, and every such case receives scrutiny
from our Gynecology colleagues. We understand that there
may be rare reasons for performing LEEPs that are nonguideline adherent (such as a patient who has a long history of noncompliance with screening guidelines). However, if the number
of nonguideline adherent LEEPs continues to rise, the authors
plan to discuss this with the specific clinicians responsible.
For those cases with the guideline adherent indication of
persistent LSIL, the duration prior to LEEP doubled from a
median of 25.5 months (mean: 28.6 months) preintervention
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Table 3. Number and Percentage of Guideline Adherent and Nonguideline Adherent LEEPs and Number of LEEPs Per Year.*,y
Guideline Adherent
LEEPs (%)

Year
2011
2012
2013: preintervention (9 months)
Total preintervention (33 months)
2013: postintervention (3 months)
2014
2015
Total postintervention (27 months)

126
73
51
250
8
38
41
87

Nonguideline Adherent LEEPs
or Indeterminate Pathology (%)

(82)
(68)
(75)
(76)
(100)
(97)
(95)
(96)

29
35
17
81
0
1
2
3

(17)
(32)
(25)
(24)
(0)
(3)
(5)
(4)

Total

Average LEEPs
Per Month

155
108
68
331
8
39
43
90

12.9
9
7.5
10.0
2.7
3.3
3.6
3.4

Abbreviation: LEEPs, loop electrosurgical excision procedures.
*Data from both the preintervention and postintervention periods are compared.
y
P < .0001; w2 test.

Table 4. The Percentage of LEEPs Adherent to Guidelines Pre- and
Postintervention by Clinician.
% of Guideline Adherent LEEPs
Clinician
A
B
C
D
E
F
G
H
I

Preintervention, %

Postintervention, %

100
64
88
83
83
80
100
92
67

100
96
100
100
90
100
100
92
100

Abbreviation: LEEPs, loop electrosurgical excision procedures.

to 54 months (mean: 55.4 months) postintervention which was
highly statistically significant (P < .0073; Wilcoxon KruskalWallis test). In addition, there were no cases postintervention in
which the indication for the LEEP was risk factors, patient
preferences, atypical endometrial or endocervical cells on Pap
test, ECC with LSIL, or inconclusive biopsies. There were only
3 nonguideline adherent cases in the post-intervention period—
inappropriate duration (LSIL of less than 24 months duration),
ASC-H Pap test without a confirmatory biopsy, and colposcopy
findings only without confirmatory Pap test or biopsy.
The individual percentage of guideline-adherent LEEPs by
gynecologist for both preintervention and postintervention are
shown in Table 4. This table only includes those clinicians for
whom data were available preintervention and postintervention
and shows a dramatic drop for most individuals. New faculty
hired postintervention were all 100% compliant. Although
there were statistically significant differences in practice patterns before the intervention (P < .0001; w2 test), postintervention, these differences were not significant. Results of histology
on our LEEP cases preintervention and postintervention are
compared in Table 5. During the preintervention period, HSIL
was found on only 44% of our cases, whereas after the intervention, HSIL was found in 60% of cases (a 16% rate

Table 5. Outcomes for LEEPs Preintervention and Postintervention.*
Count (%)
Preintervention, January 2011 to
September 2013
Postintervention, October 2013 to
December 2016
Total

HSIL
Present

HSIL
Absent

Total

146 (44%) 185 (56%) 331
54 (60%)

36 (40%)

90

200

221

421

Abbreviations: HSIL, high-grade squamous intraepithelial lesion; LEEP, loop
electrosurgical excision procedure.
*P < .0087, 2-tailed Fisher Exact test.

improvement). These results were highly statistically significant (P < .0087; 2-tailed Fisher exact test).

Discussion
The educational and peer-leader dashboard intervention
prompted a swift and persistent change in behavior in gynecologists, women’s health nurse–practitioners, and pathologists. The number of LEEPs fell from approximately 10 per
month to 3 to 4 per month with corresponding increase in
adherence to guidelines. Furthermore, the percentage of cases
with the desired outcome rose from 44% to 60%. Our intervention definitely improved outcomes. Although we cannot
prove that we decreased complications and future adverse
pregnancy outcomes, this would appear to be likely. The
national birth registry of Finland provides an evidence basis
for the number needed to harm calculation of 1 additional
premature birth for every 38.5 preceding LEEP procedures.11
Based on our data preintervention and postintervention, we
model that intervention spared unneeded LEEPs in approximately 92 patients of whom about 75% (71) would theoretically be of reproductive age.
We recognized that some of these patients will eventually
require LEEP, especially among those with LSIL duration of
less than 24 months at the time of the LEEP. In fact, only a
quarter of the patients with LSIL duration >24 months had

6
subsequent HSIL on LEEP; therefore, continued close followup of patients with LSIL who have not yet reached 24 months
should detect these cases. The duration of follow-up for this
indication also increased in the postintervention period. It
may be useful for larger-scale studies to investigate whether
longer periods of follow-up can further improve safety. This
question is consistent with the general movement in the field
of cervical cancer prevention. The 2013 guidelines for
the prevention of cervical cancer are more conservative in
the recommendations for screening and management than the
2006 guidelines.18-20 Our findings appear to support this
more conservative approach.
The critical parts of the intervention were the collaborative,
interdisciplinary, and interprofessional review and presentation
of the preintervention data and the continuing collaborative
postintervention review. Clinicians need compelling reasons
to change behaviors that consistently favor additional intervention. The human bias that accepts current practice as justified
and reasonable likely means that data will often be important
when the goal is to address deviations from standard practice.21
We anticipated that clinical staff, including physicians and
nurse practitioners, would question the safety of abandoning
nonguideline practices that favored early intervention. Our data
revealed clearly that patients received no additional diagnostic
benefit from more aggressive nonguideline interventions and
strongly suggested that there were instead probably risks that
had not been considered by participating clinicians, including
unneeded procedures, premature procedures that may or may
not have been needed at a later time, and possibly, increased
risk of premature delivery in the patients who were still in their
reproductive years.
Even when there are strong guidelines, our experience suggests an important role for local data when there are questions
about current practice.22,23 Based on our experience, change
requires addressing clinician concerns with reference to data.23
Clinicians justifiably seek to avoid missing a detectable case of
advanced cervical cancer. The mistaken idea that more is
always better is an accepted cause of overtreatment.24,25 However, this assumption in the treatment of HSIL was not supported by our data. Instead, our data suggest no additional value
and probable risk.
The specific case of CIN 1-2 revealed a nomenclature etiology for nonguideline behavior that is worth discussing because
it suggests a need for pathologists to change behavior. Most
pathologists in our institution considered CIN 1-2 to be closer
to ‘‘LSIL’’ than ‘‘HSIL’’ and believed there is a communication benefit to expressing the potential presence of an intermediate finding. In contrast, gynecologists felt they must react
to a CIN 1-2 in the report no differently than to a CIN 2 or highgrade lesion. This is understandable in terms of the goal of
screening, the preventability of this disease, and the differential
medical-legal consequences of overtreatment compared to
undertreatment. Thus, pathologists need to understand that the
terminology used in a report has implications for treatment.
Following the intervention, we required a second pathologic
review for CIN 1-2 diagnoses in our institution, and to date, we
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have eliminated the equivocal biopsy result as an indication for
LEEP in our patients.
Our data have some important limitations. This study is
limited to a single institution and its outreach network; however, a large-scale review of treatment of carcinoma in situ
(CIN 3, HSIL) at the Michigan Cancer Surveillance Program
noted wide variation in the treatment of HSIL with more
aggressive treatment, such as LEEP and cone, favored over less
aggressive treatment.2 In addition, we deliberately did not consider cost implications (either direct costs of the procedure or
indirect costs of adverse pregnancy outcomes) as part of the
study because the goal was improved care and not cost savings.
However, we definitively decreased the number of procedures
and probably decreased risk for adverse pregnancy outcomes,
so theoretically we should have also decreased costs, thus
achieving Berwick’s Triple Aim.26

Summary and Conclusion
Significant data reside on pathology AP LIS systems that can
be used to improve high-value care. In 1 example, we used
pathology data to change practice patterns for both pathologists
and gynecologists in order to decrease unnecessary LEEPs for
treatment of cervical neoplasia. Pathologists reduced equivocal
HSIL cases by requiring a second review while gynecologists
improved adherence to guidelines. This process improved
patient outcomes and theoretically reduced complications and
costs. We advocate that pathologists use such data in interdisciplinary and interprofessional interventions to improve value.
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